Omics! Omics!

A computational biologist's personal views on new technologies & publications on genomics & proteomics and their impact on drug discovery

Saturday, June 13, 2026

Long Reads for Rare Diseases Hits New England Journal of Medicine

›
Alexander Hoischen and colleagues have a brief piece in New England Journal of Medicine that published early this morning , in conjunction w...
1 comment:
Friday, June 12, 2026

Craig Venter Reflections: Building & Redesigning Genomes

›
The last bit of Craig Venter's career a followed, often a bit green with envy, was his work to build genomes.  This all revolved around ...
Thursday, June 11, 2026

Craig Venter Reflections: Human Genome

›
Few bombshells have hit genomics like the day in May 1998 when Craig Venter and Applied Biosystems announced he would be launching Celera Ge...
Wednesday, June 10, 2026

Craig Venter Reflections: Small Genomes

›
In the early 1990s, Craig Venter left the NIH over disputes around the patenting of ESTs.  Investors backed him, but then William Haseltine ...
Tuesday, June 09, 2026

Craig Venter's Genomics Revolution: Setting the Stage

›
I am overdue in getting back to my very personal review of how the recently passed J. Craig Venter made a huge impact on genomics science.  ...
Monday, June 01, 2026

FoG to Roll into Boston Seaport Wednesday & Thursday

›
The Festival of Genomics, Biodata and AI - thankfully known as FoG and not FogBA or FogBDA - will be at the Boston convention center this W...
Sunday, May 31, 2026

London Calling: Long-Term R&D

›
Now to run through the long term technical projections from Oxford Nanopore's Tech Talk.  Well, projection is probably not the correct w...
‹
›
Home
View web version

About Me

My photo
Keith Robison
Dr. Robison spent 10 years at Millennium Pharmaceuticals working with various genomics & proteomics technologies & working on multiple teams attempting to apply these throughout the drug discovery process. He spent 2 years at Codon Devices working on a variety of protein & metabolic engineering projects as well as monitoring a high-throughput gene synthesis facility. After a brief bit of consulting, he rejoined the cancer drug discovery field at Infinity Pharmaceuticals in May 2009. In September 2011 he joined Warp Drive Bio, a startup applying genomics to natural product drug discovery. In February 2019 he joined Ginkgo Bioworks, a synthetic biology company. Other recurring characters in this blog are his late loyal Shih Tzu Amanda, his current Shih Poo Lily and his now adult son alias TNG (The Next Generation). Dr. Robison can be reached via his Gmail account, keith.e.robison@gmail.com You can also follow him on Twitter as @OmicsOmicsBlog.
View my complete profile
Powered by Blogger.